# A carbapenem compound, preparation and use.

## Abstract
The compound of formula II

## Claims
Claims 1. The compound of formula II EMI24.1 namely 5R,65 3 2 Z 2 aminoethoxycarbonyl ethenyl thio 6 R l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid. 2. A pharmaceutical composition comprising the compound of formula II as defined in claim 1 and a pharmaceutically acceptable carrier there for. 3. A composition according to claim 2, characterised by being adapted for oral administration. 4. A composition according to claim 3, characterised by being in the form of a tablet or a capsule. 5. A composition according to any of claims 2 to 5, characterised in that it contains from 50 to 500 mgs of the compound of formula II . 6. A process for the preparation of the compound of formula II as defined in claim 1, which process comprises a the reaction, in the presence of an acid acceptor, of a cleavable ester of a compound of formula IV EMI25.1 with a compound of formula V H C C CO2CH2X V wherein X is an amino group or a precursor thereof and any amino or hydroxy group is optionally protected or b the hydrolysis of a compound of formula VI or salt or cleavable ester thereof EMI25.2 wherein R1 is a hydrogen atom, or a C16 alkyl, aryl or aryl C1 6 alkyl group or c the reaction of a compound of formula XI EMI25.3 wherein Ra is a carboxy protecting group and R7 isC1 6 alkyl, C3 7 cycloalkyl, C3 7 cycloalkyl C1 6 alkyk, aryl C1 6 alkyl, heterocyclyl C1 6 alkyl, heteroaryl C16 alkyl, heterocyclyl, heteroaryl, aryl, C26 alkenyl or C26 alkynyl group, any of groups R7 being optionally substituted with a compounds of formula XII EMI26.1 or reactive derivative thereof, wherein X is an amino group or a precursor thereof, and any amino or hydroxy group is optionally protected or d the elimination of the elements of R8R9R10p 0 from a cleavable ester of a compound of formula XIII EMI26.2 wherein R8, R9 and R10 are independently phenyl or methoxyphenyl, and wherein any amino or hydroxy group is optionally protected and thereafter, where necessary, cleaving the cleavable ester and removing any protecting group. 7. A process according to claim 6 a , characterised in that the cleavable ester in the p nitrobenzyl ester and X is p nitrobenzyloxycarbonylamino. 8. A process according to claim 6 a or 7, characterised in that the acid acceptor is potassium carbonate. 9. A process according to any of claims 6 a , 6 b , 7 or 8, characterised in that the C 8 hydroxy group of the compound of formula IV is protected by f rmyl andR1 in formula VI is hydrogen. 10. The compound of formula II for use in the treatment of a bacterial infection in an animal.

## Description
NOVEL COMPOUNDS, THEIR PREPARATION AND USEThis invention relates to novel 7 oxo 1 azabicyclo 3.2.0 heptene derivatives and in particular to such derivatives with C 3 carboxyvinylthio substituents.This invention further relates to processes for their preparation and to compositions containing them. These derivatives are of use in the treatment of bacterial infection.European Patent Application Publication No 0024832 discloses inter alia compounds of formula LI EMI1.1 and pharmaceutically acceptable salts and cleavable x esters thereof wherein R is OH or OS03H or a pharmaceutically acceptable salt or C1 4 alkyl ester thereof, and Ry represents a hydrogen atom, a pharmaceutically acceptable salting ion or a C1 4 alkyl or amino C14 alkyl group.We have now found that one compound within formula I , 5R,6S 3 2 Z 2 aminoethoxycarbonyl ethenylthio 6 R l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid, shows superior efficacy, for example antibacterial activity and or stability, to closely related compounds specifically disclosed in the aforementioned European PatentApplication. In particular, the compound of the present invention shows an unexpected and significant improvement in antibacterial activity over the products ofExamples 18 and 20 of the aforementioned European PatentApplication, namely the SR, 6S and 5R,6R 3 2 Z 2 aminoethoxycarbonyl ethenylthiol 6 I S l hydroxy ethyl 7 oxo l azabicyclo 3.2.0 hept 2 ene 2 carboxylic acids.Accordingly, the present invention provides the compound of formula II EMI2.1 having 8R,6S,5R stereochemistry, and cis stereochemistry in the double bond of the C 3 side chain.The compound of formula II is most suitably presented in the form of a zwitterion that is EMI2.2 In another aspect the present invention provides a process for the preparation of a compound of formula II , which process comprises the reaction, in the presence of an acid acceptor, of a cleavable ester. of a compound of formula IV EMI3.1 with a compound of formula V H C r C CO2 CH2 CH2 X V wherein X is an amino group or a precursor thereof and any amino or hydroxy group is optionally protected and thereafter cleaving the cleavable ester and removing any protecting groups.Suitable precursors of the amino group include the azido and nitro groups which are convertible to amino in a conventional manner.In one embodiment,the C 8 Hydroxy group of the compound of formula IV may be protected as a formate.Suitable acid acceptors are carbonates and bicarbonates such as anhydrous potassium carbonate. The reaction is generally performed in a dry polar solvent such as dimethylformamide. Suitably, the reaction is preformed at a non extreme temperature, for example, 30 C to 60 C more suitably lO0C to 4O0C and preferably at ambient temperature. The compounds of formula IV above and VI and VII below may be prepared by the methods of European PatentApplication No. 0024832.In another aspect, the present invention provides a process for the preparation of a compound of the formula II , which process comprises the hydrolysis of a compound of formula VI EMI4.1 or salt or cleavable ester thereof, wherein R1 is a hydrogen atom, or a C16 alkyl, aryl or aryl C16 alkyl group and thereafter cleaving any cleavable ester.The hydrolysis may be performed by a standard methods for example,using an alkali or alkaline earth metal salt in aqueous solution. Suitable salts include sodium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate and potassium hydroxide. Of these, sodium hydroxide is preferred when the C 2 carboxy group is esterified.Suitable salts for the compounds of the formula VI include inorganic salts for example metal salts such as silver or mercuric salts, or alkali metal salts such as lithium or sodium salts, and organic salts such as tertiary amine salts.When R is or includes aryl, a preferred aryl group is phenyl. The compounds of formula VI may be prepared by the reaction of a cleavable ester of a compound of formula VII EMI5.1 having BS stereochemistry, i.e. inverted compared with that at C 8 of the compound of formula II with a a compound of formula VIII R1CO2H VIII wherein R1 is as hereinbefore defined b a compound of formula IX R2O. CO.N N. CO. OR TX wherein RÃª and R are independently C1 6 alkyl, aryl C16 alkyl or aryl and c a compound of formula X EMI5.2 wherein L, M and N are independently zero or one andR4, R5 and R6 are independently C1 6 alkyl, aryl C1 6 alkyl or aryl and thereafter, if necessary, cleaving a cleavable ester. A preferred compound of formula VIII is formic acid.Suitable compounds of formula IX include those wherein R2 and R3 are independently selected from methyl, ethyl, propyl, butyl, benzyl and phenyl. It is generally convenient that R and R3 each represent the same moiety.Particularly suitable compounds of formula IX include those wherein R2 and R3 each represent an ethyl, t butyl or isopropyl group.Suitable compounds of formula X include those wherein the R4, R5 and R6 groups are selected from methyl, ethyl, n propyl, n butyl, benzyl, phenyl and methoxyphenyl groups. It is generally convenient that R4,R5 and R6 each represent the same moiety.Favoured compounds of fprmula 2 include tri aryl phosphines and tri alkyl phosphites. Particularly suitable compounds of the formula C include triphenylphosphine, trimethylphosphite and triethylphosphite, of these triphenylphosphine is preferred.In general, in the reaction of the compounds VII z3, it has proved convenient to use one equivalent of the compound of formula VIT , approximately two equivalents of the compounds of formulae IX and z4, and from two to five equivalents of the compound of formula VIII . The reaction is performed in an inert organic solvent which should be aprotic and substantially unreactive towards the reagents involved.Suitable solvents include tetrahydrofuran, dioxan, 1,2 dimethoxyethane, benzene, toluene and mixtures thereof. The reaction is normally performed at a nonextreme temperature such as 60 C to 100 C, more suitably from about 100C to 50 C, and most conveniently at ambient temperature.In another aspect the present invention provides a process for the preparation of a compound of formula II , which process comprises the reaction of a. compound of formula XI EMI7.1 wherein Ra is a carboxy protecting group and R7 is C1,6 alkyl, C3 7 cycloalkyl, C3 7 cycloalkyl C1 6 alkyl, arylC1 6 alkyl, heterocyclyl C1 6 alkyl, heteroaryl C1 6 alkyl, heterocyclyl, heteroaryl, aryl, C2 6alkenyl orC2 6 alkynyl group, any of groups R7 being optionally substituted with a compound of formula XII EMI7.2 or reactive derivative thereof, wherein X is an amino group or a precursor thereof and any. amino or hydroxy group is optionally protected and thereafter removing any protecting group s , such as the carboxy protecting group. Suitably the C S hydroxy group is protected as a formate. This reaction may be performed in any solvent that is substantially inert during the reaction, for example, tetrahydrofuran, dimethylformamide, dioxan, hexamethyl phosphoramide, dimethoxyethane or dimethoxydiethyl etcher. Of these solvents dimethylformamide is preferred. AlternativelyJ we have found it useful to use a phase transfer catalyst. Particularly suitable phase transfer catalysts include tetra n butyl ammonium bromide, cetylbromide and cetyltriethylammonium chloride suitable solvents include halogenated water immiscible solvents such as chloroform in the presence of water.The reaction is normally performed at ambient or a depressed temperature, for example 200C to 700C, and preferably between OOC and 500C. However, when using a phase transfer catalyst it is preferable to conduct the reaction between 0 C and ambient temperature.When the thiol of formula XII is used, the reaction is normally carried out in the presence of a base.Examples of such bases include sodium hydride, sodium hydroxide, sodium alkoxide such as methoxide, ethoxide or butoxide, sodium amide, potassium hydroxide, potassium alkoxide such as methoxide ethoxide or butoxide, potassium amide, and trialkylamines such as triethylamine and tri n propylamine. Of these, triethylamine is preferred. Preferably, the base is present in an amount of at least 0.9 equivalents, more preferably between 1.0 and 1.2 equivalents per mole of the thiol compound.Instead of using a base in the reaction, a reactive derivative of the thiol may be used, preferably the reactive derivative is a salt of the thiol, in particular an alkali metal salt such as sodium or potassium. The amount of thiol compound of the formula XII or reactive derivative thereof is generally between 1.0 and 1.5 moles per mole equivalent of the compound of the formula XI .Suitable carboxy protecting derivatives fox the groupC02Ra include salts, esters and anhydride derivatives of the carboxylic acid. The derivative is one which may readily be cleaved at a later stage of the reaction.Salts need not be pharmaceutically acceptable.When R7 is or includes aryl, a prefferred aryl group is phenyl a preferred heterocyclyl group is tetrahydro furaryl and a preferred heteroaryl group is thienyl.In another aspect the present invention provides a process for the preparation of a compound of formula II , which process comprises the elimination of the elements of R8R9R10P 0 from a cleavable ester of a compound of formula XIII EMI9.1 wherein R8, R9 and R10 are independently phenyl or methoxyphenyl, and wherein any amino or hydroxy group is optionally protected and thereafter cleaving the cleavable ester.Suitably, this process is performed by heating the ester of the compound of formula XIII in an inert organic solvent, for example, in a solvent such as toluene, preferably under substantially anhydrous conditions.Temperatures of 9OOC to 1200C and more suitably 1000C to 1100C may be employed. The compounds of formula XIII may be prepared by methods analogous to those disclosed in European PatentApplicatbn Publication Nos 0008514 and 0003740.In the processes of this invention any amino group present can be conveniently protected in conventional manner, for example as a p nitrobenzyloxycarbonyloxyamino group.Suitable cleavable esters of the compounds of formulae IV , VI , VII and VIII include those convertible by chemical or bidlogicals methods to the free acid, such as by in vivo hydrolysis, enzymic hydrolysis, hydrogenolysis, hydrolysis, electrolysis and photolysis.Suitably, the carboxylic acid is esterified by a group of sub formulae a f EMI10.1 wherein A1 is a hydrogen atom, a C1 6 alkanoyl or an alkyl, alkenyl or alkynyl group of up to 3 carbon atoms A2 is a hydrogen atom or a methyl group A3 is a phenyl group or a phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, methyl or methoxy group A4 is a hydrogen atom or a phenyl group or a phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, methyl or methoxy group A5 is a hydrogen atom or a methyl group A6 is a C1 4 alkyl, phenyl or C1 4 alkoxy group,or A5 is joined to A6 to form a phthalidyl, dimethylphthalidchlor dimethoxyphthalidyl group A is a. C1 4 alkyl, phenyl, chlorophenyl 8.or nitrophenyl group A is a C 1 4 4 alkyl or phenyl group A9 is a C14 alkyl or phenyl group A is C1 4 alkyl and A11 is C1 4 alkyl or CHAÃAÃª is phenyl or bromophenacyl group.Favourably AÃ is a hydrogen atom or a methyl, ethyl, vinyl or ethenyl group. Favourably AÃª is a hydrogen atom. Favourably A is a phenyl, p bromophenyl, p methoxyphenyl or p nitrophenyl group. Favourably A4 is a hydrogen atom. Favourably A6 is a methyl, t butyl or ethoxy group, or is joined to A5. Favourably, A7 is a methyl group.Preferred groups of the sub formula a include the methyl, ethyl and acetonyl groups.Preferred groups of the sub formula b include the benzyl and p nitrobenzyl groups.Preferred groups of the sub formula c include the acetoxymethyl, pivaloyloxymethyl, a ethoxycarbonyloxymethyl and phthalidyl groups. A preferred group of the sub formula d is the methoxymethyl group.Preferred groups of the sub formula e include the trimethylsilyl, tert butyldimethylsilyl and tertbutyldiphenylsilyl groups.A preferred group of the sub formula f is p methoxycarbonylbenzyl.Particularly preferred esterifying groups are the p nitrobenzyl and phthalidyl groups. Pharmaceutically acceptable in vivo hydrolysable esters are those esters which hydrolyse in the human body to produce the parent acid or its salt. Such esters may be identified by administration to a test animal such as a rat or mouse by intravenous administration and thereafter examining the test animal s body fluids for the presence of the compound of the formula II or its salt.Suitable esters of this type include those of subformula c as hereinbefore defined.When used in the treatment of a bacterial infection, the compound of formula II is preferably administered in the form of a pharmaceutical formulation.Therefore in a further aspect, the present invention also provides a pharmaceutical composition which comprises a compound of formula II and a pharmaceutically acceptable carrier therefor. The compositions of this invention may be prepared by conventional methods of preparing antibiotic compositions and in conventional manner may be adapted for oral, topical or parenteral administration.The compositions of this invention are conveniently in the form of a unit dose composition adapted for oral administration.Alternatively, the compositions of this invention are in the form of a unit dose composition adapted for administration by injection.Unit dose forms according to this invention will normally contain from 50 to 500 mgs of a compound of this invention, for example about 62.5, 100, 125, 150, 200, 250, or 300 mgs. Such compositions may be administered from 1 to 6 times a day or more conveniently 2, 3 or 4 times a day so that the total daily dose for a 70 kg adult is about 200 to 2000 mg, for example about 400, 600, 750, 1000 or 1500 mg. The carriers used in the compositions of this invention may include diluents, binders, disintegrants, lubricants, colours, flavouring agents and preservatives in conven tional manner. Thus suitable agents include lactose, starch, sucrose, calcium phosphate, sorbitol,polyvinyl pyrrolidone, acacia, gelatin, tragacanth or the like, potato starch or polyvinylpolypyrrolidone, magnesium stearate and sodium lauryl sulphate. Orally administrable forms of the compositions of this invention are most suitably in the form of unit dose units such as tablets or capsules. The compounds and compositions of this invention may be used in the treatment of a bacterial infection in animals, such as mammals including humans, for example,infections of the respiratory tract, urinary tract or soft tissues, or mastitis in cattle. Such compositions may be administered to susceptible gram positive or gram negative bacteria such as strains of StaPhylococcus aureus,Klebsiella aerooenes and Escherichia coli.Therefore, in a further aspect, the present invention provides a method for the treatment of a bacterial infection in an animal, which method comprises the administration to said animal of a non toxic, antibacterially effective amount of a compound of formula II or a pharmaceutical formulation thereofThe present invention will now be illustrated by the following Examples and data. Example 1 a p Nitrobenzyl 5R,6S 3 Z 2 2 N p nitrobenzyloxycarbonylamino ethyloxycarbonyl ethenylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate.EMI15.1 p Nitrobenzyl 5R,6S 3 E 2 acetamidoethenylthio 6 R 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate e1 100 mg was dissolved in 1,4 dioxan 5 ml containing water 10 drops and stirred at room temperature for 5 minutes with Nbromoacetamide 31 mg . Chloroform was added and the organic phase was washed with pH 7o0, 0.05 M phosphate buffer, saturated sodium chloride solution and dried over anhydrous magnesium sulphate, Filtration and removal of the solvent at reduced pressure afforded the crude thiol e2 , as a pale yellow oil. The crude thiol e2 was dissolved in dry dimethylformamide 5 ml and stirred at room temperature for 15 minutes with 2 i nitro benzyloxycarbonylami no ethyl propio ate 80 mg and anhydrous potassium carbonate 31 mg . Ethyl acetate was added and the organic solution washed with water, saturated sodium chloride solution and dried over anhydrous magnesium sulphate. After filtration, the solvent was removed at reduced pressure to yield an oil, which was chromatographed over silica gel 14 gm .Elution with a gradient of O to 2 ethanol chlorofoim gave the title compound as a white solid 40 mg , max. KBr 3410, 1775, 1720 shoulder , 1700, 1603, 1520 cm ., Ã§ EtOll 335 nm Em 10650 , 265 nm Em 11710 , 5H d7 DMF 1.26 3H, d, CH3CH , 3.4 3.8 m, 4 CH2 6 CH CH2 , 4.12 1H, broad quintet, 8 CH , 4.28 2H, m, CH2 , 4.40 1H, dt, 5CH , 5.27 2H, s, CH2 Ar , 5.50 2H, AB, CH2Ar , 6.10 1H, d, J 9.3 Hz, cis CH C , 7060 1H, broad t, exchanges with D20, NH, 7.67 2H, d, aromatic protons , 7.75 8900 3H, m, CH C aromatic protons , 8.23 8036 4H, 2 x d, aromatic protons .b 5R,6S 3 Z 2 2 aminoethyloxycarbonyl ethenylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acidEMI16.1 The ester e3 35 mg was dissolved in 1,4 dioxan 20 ml , pH 7,0 0.05 M phosphate buffer 3.75 ml and water 3 ml and shaken with hydrogen at ambient temperature and pressure for 2 hours in the presence of 5 palladium on charcoal catalyst 60 mg . The reaction solution was filtered over Celite, washing well with water. The filtrate was then evaporated to smaller volume at reduced pressure and washed with ethyl acetate 3 x 50ml . The solution was then chromatographed over Hp 20, eluting with a gradient of O 20 ethanol water.The column fractions were monitored by n.v. and those possessing the desired absorption may 324 nm were combinedThe resulting solution was estimated to contain 4.7 mg title compound e4 based on Em 179000 at max 324 nm in the u.v. spectrum. Example 2 a p Nitrobenzyl 5H,6S 3 2 2 p nitrobenzyloxycarbonylamino ethosvcarbonyl ethemflthio F6 r R 1 formyloxyethyl 7 oxo 1 aza bicyclo 3.2.0 hept 2 ene 2 carboxylateEMI17.1 p Nitrobenzyl 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0. hept 2 ene 2 carboxylate e5 377 mg was dissolved in aqueous 1,4 dioxan 50 ml and stirred at room temperature for 5 minutes with N bromoacetamide 109.5 mg .Chloroform was added and the organic phase was washed with pH 700, o.05 M phosphate buffer, saturated sodium chloride solution and dried over anhydrous magnesium sulphate. Filtration and removal of the solvent at reduced pressure afforded the crude thiol e6 as a pale yellow oil, max. CHCl3 1781, 1723, 1610, 1560, 1525, 1355, 1340 1 cm The crude thiol e6 was dissolved in dry dimethylformamide 10 ml and stirred at room temperature for 15 ininates with 2 p nitrobenzyloxycarbonylamino ethyl propion ate 350 mg and anhydrous potassium carbonate 109.5 mg . Ethyl acetate was added and the organic solution washed with water, saturated sodium chloride solution and dried over anhydrous magnesium sulphate.After filtration, the solvent was removed at reduced pressure to yield a yellow oil, which was chromatographed over silica gel 20 gm . Elution with ethyl acetate afforded the crude product as a pale yellow foam 310 mg .This foam was rechromatographed over silica gel 15 gm , eluting with chloroform. The resulting pale yellow oil, on trituration with diethyl ether afforded a pale yellow solid 155 mg . This consisted of p nitrobenzyl 5R,6S 3 2 2 p nitrobenzyloxycarbonylaminoethoxycarbonyl ethenylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate as a mixture of the Z isomer e7 and the E isomer e8 in the approximate ratio 9 1 max. EtOH 334 nm 17,746 , 265 nm Em 18, 579 , max x CHBr3 3400, 1781, 1720, 1605, 1520, 1345 cm 5H CDCl3 1.47 3H, d, CH3CH , 3.24 1H, dd, CHa , 3.4 3.6 4H, m, CH2NH 6 CH 4 CHb , 4.30 3H, m,C02CH2 5 CH , 5.20 2H, s, CH2Ar , 5.22 5.58 4H, q m, CH2AR 8 CH NH , 6.00 1H, d, J 10.5 Hz, cis CH C , 7.26 1H, d, J 10.5Hz, cis CH , 7.49 2H, d, aromatic protons , 7.66 2H, d, aromatic protons , 8.07 1H, s, CHO , 8.13 8030 4H, 2x d, aromatic protons . The E isomer shows inter alia 5 6.12 d, J 15 Hz, transCH C , 7.77 d, J 15 Hz, trans CH C . b 5R,6S 3 Z 2 2 aminoethyloxycarbonyl ethenylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid e9 and 5R,6S 3 Z 2 2 aminoethyloxycarbonyl ethenylthio 6 R 1 hydroGyethyl 7 oxo 1 azabicyclO 3E2.01hept 2 ene 2 carboxylic acid e4 EMI19.1 The mixture of esters e7 and e8 500 mg was dissolved in 194 dioxan 75 ml , water 23 ml and pH 7.0, 0.05 M phosphate buffer 23 ml and shaken with hydrogen in the presence of 5 palladuim on carbon catalyst 750 mg at ambient temperature and pressure for 3.5 hours. The solution was filtered over Elite, washing well with water, and evaporated to smaller volume at reduced pressure.The filtrate was washed with ethyl acetate 3 x 250 ml and evaporated again at reduced pressure in order to remove ethyl acetate0 The resulting solution, which was estimated to contain 125 mg of the formyloxy derivative e9 based on Em 17,000 at 325 nm in the u.vO spectrum, was stirred at pH 9.0 and room temperature for 3.5 hours0 The pH was then readjusted to 700 and the solution evaporated to small volume at reduced pressure. Chromatography overHP 20, eluting with a gradient of O to 5 ethanol water afforded an aqueous solution containing the pure 5R, 6S 3 Z 2 2 amino ethyloxycarbonyl ethenylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid e4 .Evaporation to small volume followed by lyophilisation yielded. the product as a white fluffy solid 409 mg , max H2O 325 nm Em 10,550 In another experiment, the crude formyloxy derivative e9 , obtained by hydrogenolysis of the mixture of esters e7 and e8 , was purified by chromatography over HP 20, eluting with a gradient of O to 20 ethanol water. Lyophilisation afforded 5R76S 3 Z 2 2 aminoethyloxycarbonyl ethenylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid e9 as a white fluffy solid, max H20 325 nm im 15,033 . This sample contained a small amount of the E isomer by h.p.l.c. , which could be removed, if desired, by further chromatography. Demonstration of EffectivenessEMI21.1 EMI21.2 tb SEP stereochemistry tb Compound SEP A SEP RA SEP CH3 SEP SEP B SEP R SEP SEP H SEP 8S,6R,5R tb SEP R SEP R SEP tb Compound SEP B SEP RA SEP H SEP RB SEP SEP OH SEP h SEP R SEP 8R,65,5R tb SEP CHR tb Compound SEP C SEP RA SEP H SEP RB SEP SEP OH SEP 8S,6S,5R tb SEP CH5 tb Antibacterial Activity in vitro MIC vg ml Compound AOrganismEscherichia coli JT4R 6.2 JT20R 6.2 II E96R 0.8 Ba78R 1.6Klebsiella aerogenes VA2R 25 Ba95R 6.2 185R 3.1 II 192R 6.2 Staphylococcus aureus ATCC 25923 0.1 Staphylococcus aureus T100 0.2 II II Smith 0.2 150 0.2 it MB9 0.2 T71 0.1 II N71MR 0.8 N36MR 0.4 68 8484 0.2Compound BExcheridhia coli JT4R 0.1 JT56R 0.2 JT177R 0.2 n Ba78R 0.1Klebsiella aerogenes Va2R 0.4 Ba95R 0.4 Dul85R 0.2 Dul192R 0.2Staphylococcus aureus T2p 0.1 T100p 0.02 T120p 0.02 T97p 0.1 T118p 0.05 it MANSTK 33269 0.4 N36R 0.1Compound CEscherichia coli JT39 3.1Klebsiella aerogenes A 3.1Staphylococcus aureus Russell 0.4Staphylococcus aureus 1517 6.2 Tissue Stability ValuesA preparation of 2 mouse kidney homogenate was mixed with equal volumes of a 200 Ug ml solution of the antibiotic to be tested. The stability of the antibiotic at 370C was studied by removal of aliquots and subjecting them to a high pressure liquid chromatographic analysis. The values are given in figures relative to that obtained for MM13902 of U.K. PatentNo. 1489235. The values are given in figures relative to that obtained for MM13902 which is taken as standard 1.0 . Values greater than 1.0 reflect the fold increase in stability relative to MM13902. Tissue Compound A Compound B MM13902 Mouse Kidney 1.3 2.4 1.0Human Kidney 1.2 2.2 1.0Antibacterial Activity in vivo against ExperimentalMouse infectionsCD50 mg kg total dose Compounds dosed at 1 and 5 hours past infection.Organism Compound A Compound BStaph. aureus Smith 4.5 0.4E. coli E96R 66 13.0